On April 8, the List of 1000 Top Chinese Innovative Enterprises was officially released at the press conference for the “List of 100 Top, 1000 Top and 10,000 Top Chinese Enterprises with Innovative Capacity in 2017” held at China’s Renmin University. Hansoh Pharma was included in the List of 1000 Top Chinese Innovative Enterprises.

Some 80,000 high-tech enterprises competed for this prestigious list.

The “List of 100 Top, 1000 Top and 10,000 Top Chinese Enterprises with Innovative Capacity in 2017” was created by the “Macro - Innovation Research Team”, consisting of members from Renmin University, Central University of Finance and Economics and Chinese Academy of Social Sciences, after a year of data collection and statistical measurement.

It was the first time that full and comprehensive evaluations of the innovation capacity of more than 80,000 domestic high-tech enterprises were carried out, and special research was conducted on the top 100, top 1000 and top 10,000 Chinese innovative enterprises on that basis. This was helpful for all sectors of the society, including the government agencies and capital markets, to enhance their recognition of enterprises’ innovation capacity, but it also helpful for implementation of the innovation-driven development strategy, thus accelerating the transformation of Chinese economy, from factor-driven to innovation-driven. 

From the start, Hansoh Pharma has adhered to a science and technology-based innovation strategy, and it has earned a well-deserved place on the List of 1000 Top Chinese Innovative Enterprises.

It has been awarded the second-place prize for the Science and Technology Progress Award for two consecutive years.

It was also granted the Chinese Patent Gold Award, the highest honor in the patent field of China.

Hansoh Pharma has established two R&D centers (in Shanghai and Lianyungang respectively) and more than 10 innovation platforms, including a national-level enterprise technical center, a national-level post-doctoral research center, a national key laboratory, and a Jiangsu provincial academician workstation. While committed to cutting-edge R&D of chemical drugs, the Company is actively exploring biopharmaceutical development, and it is continuously optimizing product structure and creating a superior product portfolio.

Hansoh Pharma offered more than 40 types of products to serve patients in six key fields, namely, the anti-tumor, psychotropic, internal secretion, digestive tract, anti-infection and cardiovascular fields. The Company ranked in the top 3 in the industry in terms of independent innovation capacity. It has launched the first new drug with independent IP, Mailingda, in the market, and has more than 10 innovative drugs in different research stages. The increasingly prominent innovation results are effectively driving the transformation, upgrading and sustainable development of the Company. 

The 2017 Evaluation Report on Innovation Capacity of Chinese Enterprises was also released at the conference to provide a comprehensive analysis on the innovation capacity of Chinese high-tech enterprises.

In terms of patent quantity, the patents were distributed unevenly among the enterprises. A small number of enterprises with strong innovation capacity owned most of the patents, while many other enterprises had few patents and weak innovation capacity. According to the data, among the 1000 top Chinese high-tech enterprises, only 55 enterprises had more than 2000 patent applications, and their applications accounted for 45.3% of the total number of applications; 635 enterprises had less than 500 patent applications, and their applications accounted for only 21.4%. Among the 80,000 high-tech enterprises in the country, enterprises with more than 500 patent applications accounted for only 0.64%.

In terms of patent quality, the proportion of invention patents of Chinese high-tech enterprises was significantly lower than that of peers in developed countries (such as the USA, Japan and European countries), indicating that the patents of Chinese high-tech enterprises were not of high quality. According to the data metrics for the lists, invention patent applications of the 1000 top Chinese high-tech enterprises accounted for 59.2% of all patent applications, and the valid invention patents accounted for 41.3% of all valid patents. When the scope was expanded to 80,000 high-tech enterprises, the invention patent applications accounted for only 41.2% of all the patent applications, and valid invention patents accounted for 24.5% of all the valid patents. In contrast, the proportion of invention patents in developed countries (such as the USA, Japan and European countries) was 80% or above.